Drug intelligence / Profile preview

fenpiprane

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Fenpiprane is a small molecule drug classified as a diarylmethane and diphenylmethane derivative. It is primarily used for the treatment of functional gastrointestinal disorders, such as irritable bowel syndrome (IBS) and functional dyspepsia[4][5][9]. Fenpiprane exhibits antispasmodic and antiallergic activities, acting mainly by reducing gastrointestinal motility and secretions[1][5][9]. Its mechanism involves antagonism of acetylcholine receptors in the gastrointestinal tract, leading to decreased smooth muscle contractions and reduced digestive fluid secretion[5][9]. The exact molecular targets are not fully elucidated but its therapeutic effect is attributed to modulation of parasympathetic activity in the gut.

Other names: Fenpiprane [INN:BAN]

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on fenpiprane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fenpiprane.

Explore the full profile